Benzinga | Aug 19, 2021 11:55AM EDT

Noble Capital Markets Initiates Coverage On Lineage Cell Therapeutics with Outperform Rating, Announces Price Target of $8

Noble Capital Markets analyst Robert LeBoyer initiates coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Outperform rating and announces Price Target of $8.